Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Pediatrics
Erschienen in:

06.09.2024 | Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Evaluation and Management of Proteinuria in Children

verfasst von: Alexandria Hawkins, Rebecca R. Scobell

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review discusses the quantification, classification, and initial evaluation for proteinuria in children. Using the severity of proteinuria and associated symptoms, we provide a framework that classifies suspected causes of proteinuria to guide the pediatric providers towards appropriate work-up and referral to nephrology. Additionally, we discuss initial management and complications of idiopathic nephrotic syndrome.

Recent Findings

International clinical practice guidelines, including revised definitions for classification and treatment of nephrotic syndrome outcomes, aim to standardize the management of steroid sensitive and steroid resistant nephrotic syndrome. Investigations into the pathophysiology of different histological subtypes of nephrotic syndrome, which is currently not well understood, has identified antibodies that could inform new monitoring and management strategies.

Summary

Proteinuria is a common finding in the general pediatric setting and requires appropriate evaluation to discern between benign etiologies and underlying kidney disease. Age at presentation, family history, and associated symptoms are key factors that will inform initial work up and management, particularly the use of empiric corticosteroids.
Literatur
1.
Furth SL, Pierce C, Hui WF, White CA, Wong CS, Schaefer F, et al. Estimating time to ESRD in children with CKD. Am J Kidney Dis. 2018;71(6):783–92.PubMedPubMedCentralCrossRef
2.
Veltkamp F, Rensma LR, Bouts AHM. Incidence and relapse of idiopathic nephrotic syndrome: meta-analysis. Pediatrics. 2021;148(1):e2020029249.PubMedCrossRef
3.
Vehaskari VM, Rapola J. Isolated proteinuria: analysis of a school-age population. J Pediatr. 1982;101(5):661–8.PubMedCrossRef
4.
5.
Brandt JR, Jacobs A, Raissy HH, Kelly FM, Staples AO, Kaufman E, et al. Orthostatic proteinuria and the spectrum of diurnal variability of urinary protein excretion in healthy children. Pediatr Nephrol. 2010;25(6):1131–7.PubMedPubMedCentralCrossRef
6.
Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the national kidney foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. 2000;105(6):1242–9.
7.
Kamińska J, Dymicka-Piekarska V, Tomaszewska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit Rev Clin Lab Sci. 2020;57(5):345–64.PubMedCrossRef
8.
Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, et al. The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases. Kidney Int. 2016;90(5):1080–9.PubMedPubMedCentralCrossRef
9.
Hellerstein S, Simon SD, Berenbom M, Erwin P, Nickell E. Creatinine excretion rates for renal clearance studies. Pediatr Nephrol. 2001;16(8):637–43.PubMedCrossRef
10.
Leung AKC, Wong AHC, Barg SSN. Proteinuria in children: evaluation and differential diagnosis. afp. 2017;95(4):248–54.
11.
Imam AA, Saadeh SA. Evaluation of proteinuria and hematuria in ambulatory setting. Pediatr Clin North Am. 2022;69(6):1037–49.PubMedCrossRef
12.
Brandt JR, Jacobs A, Raissy HH, Kelly FM, Staples AO, Kaufman E, et al. Orthostatic proteinuria and the spectrum of diurnal variability of urinary protein excretion in healthy children. Pediatr Nephrol. 2010;25(6):1131–7.PubMedPubMedCentralCrossRef
13.
Habib R, Kleinknecht C. The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. Pathol Annu. 1971;6:417–74.
14.
15.
Zieg J. Pathophysiology of hyponatremia in children. Front Pediatr. 2017;16(5):213.CrossRef
16.
Zhang Y, Shen Y, Feld LG, Stapleton FB. Changing pattern of glomerular disease at Beijing Children’s Hospital. Clin Pediatr (Phila). 1994;33(9):542–7.PubMedCrossRef
17.
Viteri B, Reid-Adam J. Hematuria and proteinuria in children. Pediatr Rev. 2018;39(12):573–87.PubMedCrossRef
18.
19.
RobertJ S. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;304(7880):556–60.CrossRef
20.
Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21(11):1698–700.PubMedCrossRef
21.
Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative Glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055–64.PubMedPubMedCentralCrossRef
22.
Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 2015;30(1):96–106.PubMedCrossRef
23.
The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediat. 1981;98(4):561–4.
24.
Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2023;38(3):877–919.PubMedCrossRef
25.
26.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–276.
27.
Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332–45.PubMedCrossRef
28.
Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529–61.PubMedPubMedCentralCrossRef
29.
Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279–89.
30.
Popa L, Balgradean M, Croitoru A. Long-term study in children with steroid-resistant nephrotic syndrome progressing to end-stage renal disease. Maedica (Bucur). 2022;17(2):271–6.PubMed
31.
32.
Hogg R, Middleton J, Vehaskari VM. Focal segmental glomerulosclerosis – epidemiology aspects in children and adults. Pediatr Nephrol. 2007;22(2):183–6.PubMedPubMedCentralCrossRef
33.
Bonilla-Felix M, Parra C, Dajani T, Ferris M, Swinford RD, Portman RJ, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. 1999;55(5):1885–90.PubMedCrossRef
34.
Noone DG, Iijima K, Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392(10141):61–74.PubMedCrossRef
35.
Hingorani SR, Weiss NS, Watkins SL. Predictors of peritonitis in children with nephrotic syndrome. Pediatr Nephrol. 2002;17(8):678–82.PubMedCrossRef
36.
Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009;124(2):747–57.PubMedCrossRef
37.
Senguttuvan P, Ravanan K, Prabhu N, Tamilarasi V. Infections encountered in childhood nephrotics in a pediatric renal unit. Indian J Nephrol. 2004;14(3):85.CrossRef
38.
Krishnan C, Rajesh T, Shashidhara H, Jayakrishnan M, Geeta M. Major infections in children with nephrotic syndrome. Int J Contemp Pediat. 2017;4(2):346–50.CrossRef
39.
McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health. 1998;34(4):314–7.PubMedCrossRef
40.
Goonewardene ST, Tang C, Tan LTH, Chan KG, Lingham P, Lee LH, et al. Safety and efficacy of pneumococcal vaccination in pediatric nephrotic syndrome. Front Pediatr. 2019;13(7):339.CrossRef
41.
Alpay H, Yildiz N, Onar A, Temizer H, Ozçay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 2002;17(3):181–3.PubMedCrossRef
42.
Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, et al. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr. 2003;142(2):145–8.PubMedCrossRef
43.
Mehls O, Andrassy K, Koderisch J, Herzog U, Ritz E. Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults. J Pediatr. 1987;110(6):862–7.PubMedCrossRef
44.
Citak A, Emre S, Sâirin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 2000;14(2):138–42.PubMedCrossRef
45.
Lilova MI, Velkovski IG, Topalov IB. Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1974–1996). Pediatr Nephrol. 2000;15(1):74–8.PubMedCrossRef
46.
Kerlin BA, Blatt NB, Fuh B, Zhao S, Lehman A, Blanchong C, et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr. 2009;155(1):105-110.e1.PubMedPubMedCentralCrossRef
47.
Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994;93(1):204–11.PubMedPubMedCentralCrossRef
48.
Vivarelli M, Gibson K, Sinha A, Boyer O. Childhood nephrotic syndrome. Lancet. 2023;402(10404):809–24.PubMedCrossRef
49.
Marchel DM, Gipson DS. Adult survivors of idiopathic childhood onset nephrotic syndrome. Pediatr Nephrol. 2021;36(7):1731–7.PubMedCrossRef
50.
Croitoru A, Balgradean M. Treatment-associated side effects in patients with steroid-dependent nephrotic syndrome. Maedica (Bucur). 2022;17(2):285–90.PubMed
51.
Hama T, Nakanishi K, Shima Y, Sato M, Mukaiyama H, Togawa H, et al. Renal biopsy criterion in idiopathic nephrotic syndrome with microscopic hematuria at onset. Pediatr Nephrol. 2015;30(3):445–50.PubMedCrossRef
52.
53.
Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33(1):238–52.PubMedPubMedCentralCrossRef
54.
Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11–21.PubMedPubMedCentralCrossRef
55.
Bech AP, Hofstra JM, Brenchley PE, Wetzels JFM. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(8):1386–92.PubMedPubMedCentralCrossRef
56.
Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, et al. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron. 2015;130(3):159–68.PubMedCrossRef
Metadaten
Titel
Evaluation and Management of Proteinuria in Children
verfasst von
Alexandria Hawkins
Rebecca R. Scobell
Publikationsdatum
06.09.2024
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Pediatrics / Ausgabe 4/2024
Elektronische ISSN: 2198-6088
DOI
https://doi.org/10.1007/s40746-024-00309-1

Weitere Artikel der Ausgabe 4/2024

Evaluation and Management of Hematuria in Children

  • Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Comprehensive Collaboration in Fetal Cardiac Care: A Multidisciplinary Approach

  • Cardiology/CT Surgery (K Gist, Section Editor)

Testicular Stromal Tumors

  • Pediatric Urology (A Buchanan and G Campbell, Section Editors)

Evaluation and Management of Metabolic Alkalosis in Children

  • Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

The Evolving Landscape of Onabotulinumtoxin A Use in Pediatric Lower Urinary Tract Dysfunction

  • Pediatric Urology (A Buchanan and G Campbell, Section Editors)

Contemporary Trends in the Diagnosis and Management of Pediatric Dysphagia

  • Open Access
  • Pediatric Gastroenterology (S Saeed and E Mezoff, Section Editors)

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise